MX2021002333A - Metodo basado en proteogenomica para identificar antigenos especificos de tumores. - Google Patents
Metodo basado en proteogenomica para identificar antigenos especificos de tumores.Info
- Publication number
- MX2021002333A MX2021002333A MX2021002333A MX2021002333A MX2021002333A MX 2021002333 A MX2021002333 A MX 2021002333A MX 2021002333 A MX2021002333 A MX 2021002333A MX 2021002333 A MX2021002333 A MX 2021002333A MX 2021002333 A MX2021002333 A MX 2021002333A
- Authority
- MX
- Mexico
- Prior art keywords
- tumor
- cells
- proteogenomic
- sup
- specific antigens
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 210000004881 tumor cell Anatomy 0.000 abstract 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 abstract 2
- 108091026890 Coding region Proteins 0.000 abstract 1
- 238000003559 RNA-seq method Methods 0.000 abstract 1
- 108020003564 Retroelements Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000008029 eradication Effects 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 210000003619 mTEC Anatomy 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000000869 mutational effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000008707 rearrangement Effects 0.000 abstract 1
- 230000003614 tolerogenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4637—Other peptides or polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6872—Methods for sequencing involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/20—Sequence assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Se sabe que las células T, en particular las células T CD8, son actores esenciales en la erradicación de tumores, ya que la presencia de linfocitos infiltrantes de tumores (TIL) en varios cánceres se correlaciona positivamente con un buen pronóstico. Para eliminar las células tumorales, las células T CD8 reconocen los antígenos tumorales, que son péptidos asociados al MHC I presente en la superficie de las células tumorales, con una expresión muy baja o nula en las células normales. En la presente descripción se describe un enfoque proteogenómico mediante el uso de datos de secuenciación de ARN de muestras mTEChi cancerosas y normales equivalentes con el fin de identificar antígenos específicos de tumores no tolerogénicos derivados de (i) regiones codificantes y no codificantes del genoma, (ii) mutaciones de base única no sinónimas o inserciones/deleciones cortas y reordenamientos más complejos, así como también (iii) retroelementos endógenos, que funcionan independientemente de la carga mutacional o la complejidad de la muestra.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862724760P | 2018-08-30 | 2018-08-30 | |
PCT/CA2019/051186 WO2020041876A1 (en) | 2018-08-30 | 2019-08-28 | Proteogenomic-based method for identifying tumor-specific antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021002333A true MX2021002333A (es) | 2021-04-28 |
Family
ID=69643063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021002333A MX2021002333A (es) | 2018-08-30 | 2019-08-28 | Metodo basado en proteogenomica para identificar antigenos especificos de tumores. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11702450B2 (es) |
EP (1) | EP3844172A4 (es) |
JP (2) | JP7468911B2 (es) |
KR (1) | KR20210049150A (es) |
CN (2) | CN112639136B (es) |
AU (1) | AU2019330487A1 (es) |
BR (1) | BR112021002394A2 (es) |
CA (1) | CA3109716A1 (es) |
IL (1) | IL280651B2 (es) |
MX (1) | MX2021002333A (es) |
SG (1) | SG11202100528YA (es) |
WO (1) | WO2020041876A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111477274B (zh) * | 2020-04-02 | 2020-11-24 | 上海之江生物科技股份有限公司 | 微生物目标片段中特异性区域的识别方法、装置及应用 |
CA3173664A1 (en) * | 2020-04-14 | 2021-10-21 | Claude Perreault | Novel tumor-specific antigens for acute lymphoblastic leukemia (all) and uses thereof |
CN112331267A (zh) * | 2020-09-25 | 2021-02-05 | 浙江大学 | 一种基于质谱的不动杆菌数据库的构建方法及不动杆菌数据库 |
WO2023023840A1 (en) * | 2021-07-16 | 2023-03-02 | Université de Montréal | Novel tumor-specific antigens for cancer stem cells and uses thereof |
CN113593649B (zh) * | 2021-08-02 | 2022-09-09 | 中国人民解放军陆军军医大学第一附属医院 | 一种利用hla-i候选肽库鉴定组织中提取的天然抗原肽的方法 |
KR102694155B1 (ko) * | 2021-09-14 | 2024-08-13 | 한국과학기술원 | 막 단백질 정보를 이용한 치료 타깃 유전자 발굴 방법 및 분석장치 |
JP2024535853A (ja) * | 2021-09-17 | 2024-10-02 | ウニヴェルシテ ド モントリオール | 結腸直腸がんに対する新規の腫瘍特異的抗原及びそれらの使用 |
WO2024031181A1 (en) * | 2022-08-08 | 2024-02-15 | Université de Montréal | Novel antigens for cancer and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1020519A1 (en) | 1999-01-15 | 2000-07-19 | Introgene B.V. | Minor histocompatibility antigens and their use in the diagnosis and treatment of tumors |
JP2006129832A (ja) * | 2004-11-09 | 2006-05-25 | Aichi Prefecture | CathepsinHタンパク質由来のCD8+細胞傷害性Tリンパ球mHAエピトープペプチド及びその用途 |
CN102268089A (zh) * | 2011-07-05 | 2011-12-07 | 上海交通大学 | Agr2阻断抗体及其用途 |
GB201511191D0 (en) * | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
WO2017106638A1 (en) * | 2015-12-16 | 2017-06-22 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
AU2017261353A1 (en) * | 2016-05-05 | 2018-11-08 | Nantomics, Llc | Checkpoint failure and methods therefor |
US10350280B2 (en) * | 2016-08-31 | 2019-07-16 | Medgenome Inc. | Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore |
EP3548623A4 (en) * | 2016-11-30 | 2020-11-25 | Advaxis, Inc. | IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND THEIR USE PROCEDURES |
BR112021025943A2 (pt) | 2019-06-25 | 2022-02-08 | Univ Montreal | Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos |
-
2019
- 2019-08-28 EP EP19853634.4A patent/EP3844172A4/en active Pending
- 2019-08-28 CN CN201980056943.7A patent/CN112639136B/zh active Active
- 2019-08-28 JP JP2021536116A patent/JP7468911B2/ja active Active
- 2019-08-28 AU AU2019330487A patent/AU2019330487A1/en active Pending
- 2019-08-28 CA CA3109716A patent/CA3109716A1/en active Pending
- 2019-08-28 WO PCT/CA2019/051186 patent/WO2020041876A1/en unknown
- 2019-08-28 BR BR112021002394-1A patent/BR112021002394A2/pt unknown
- 2019-08-28 IL IL280651A patent/IL280651B2/en unknown
- 2019-08-28 CN CN202410944143.1A patent/CN118755835A/zh active Pending
- 2019-08-28 MX MX2021002333A patent/MX2021002333A/es unknown
- 2019-08-28 SG SG11202100528YA patent/SG11202100528YA/en unknown
- 2019-08-28 US US17/267,914 patent/US11702450B2/en active Active
- 2019-08-28 KR KR1020217008983A patent/KR20210049150A/ko active Search and Examination
-
2023
- 2023-02-15 US US18/169,870 patent/US20230242583A1/en active Pending
-
2024
- 2024-03-28 JP JP2024053328A patent/JP2024112795A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019330487A1 (en) | 2021-02-04 |
IL280651B1 (en) | 2024-01-01 |
WO2020041876A1 (en) | 2020-03-05 |
KR20210049150A (ko) | 2021-05-04 |
CA3109716A1 (en) | 2020-03-05 |
SG11202100528YA (en) | 2021-02-25 |
CN118755835A (zh) | 2024-10-11 |
EP3844172A1 (en) | 2021-07-07 |
US11702450B2 (en) | 2023-07-18 |
CN112639136A (zh) | 2021-04-09 |
JP2021534830A (ja) | 2021-12-16 |
CN112639136B (zh) | 2024-08-02 |
IL280651A (en) | 2021-03-25 |
EP3844172A4 (en) | 2022-08-10 |
US20230242583A1 (en) | 2023-08-03 |
JP2024112795A (ja) | 2024-08-21 |
US20210253638A1 (en) | 2021-08-19 |
BR112021002394A2 (pt) | 2021-05-11 |
JP7468911B2 (ja) | 2024-04-16 |
IL280651B2 (en) | 2024-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021002333A (es) | Metodo basado en proteogenomica para identificar antigenos especificos de tumores. | |
JP7297715B2 (ja) | 癌の個別化ワクチン | |
JP6774479B2 (ja) | 個別化癌ワクチンおよび癌ワクチンを提供する方法 | |
KR102399419B1 (ko) | T 세포 에피토프의 면역원성 예측 방법 | |
ES2888430T3 (es) | Predicción de epítopos de células T útiles para la vacunación | |
WO2012159643A1 (en) | Individualized vaccines for cancer | |
Kübler et al. | HLA‐class II haplotype associations with ovarian cancer | |
EP3473267B1 (en) | Individualized vaccines for cancer | |
Park et al. | False homozygosity results in HLA genotyping due to loss of chromosome 6 in a patient with acute lymphoblastic leukemia | |
Sun et al. | The novel fusion transcript NR5A2‐KLHL29FT is generated by an insertion at the KLHL29 locus | |
HUP9901786A2 (hu) | Eljárás helypreferált rákos áttétképződéssel kapcsolatos gének azonosítására immuno-mágneses sejtszeparáció felhasználásával | |
RU2779946C2 (ru) | Индивидуализированные противоопухолевые вакцины | |
NZ718326B2 (en) | Individualized vaccines for cancer | |
NZ617217B2 (en) | Individualized vaccines for cancer |